COPD Measurement and Management
Dr Jane McManus
Dr Seamus Linnane
Case Study
An 83 year old male with Chronic Obstructive Pulmonary Disease (COPD) attended the respiratory clinic for a routine check-up. He also has a history of basal bronchiectasis. He is an ex-smoker since the age of 50 with a 30 pack year history. His father and sister had chronic respiratory problems. The patient worked as a mechanic and had exposure to asbestos through brake linings. His current medications include tiotropium, ipratropium bromide/salbutamol nebuliser as required and lansoprazole. He takes clarithromycin and oral steroids for exacerbations of COPD and suffered four episodes, managed at home in the last year.
The patient continues to be very active and plays golf. His modified Medical Research Council (mMRC) score for breathlessness is 1/4. On examination his oxygen saturations are 96% on room air. His chest is hyperinflated but clear on auscultation. He weighs 80kg giving him a Body Mass Index (BMI) of 24.7 kg/m2. His FEV1 is 1.4 litres or 45 % predicted and there is a 17% increase with salbutamol. The patient was commenced on budesonide/formoterol twice daily and was referred for outpatient physiotherapy for further assessment and management of his respiratory disease.
A series of questionnaires were completed by the patient at this session including the COPD Assessment Test (CAT) in which he scored 13/40. He scored 1 on the modified Medical Research Council Dyspnoea Scale (mMRC). The patient scored 7 on the Hospital anxiety and depression scale (HADS). The patient also completed the St George’s Respiratory Questionnaire (SGRQ) and scored 30/100. He completed a 360 metres distance during a six minute walk test. His BODE Index is 2 which indicates a 52-month mortality of approximately 20%. The physiotherapist also assessed several other areas including the patient’s inhaler technique, airway clearance and breathlessness management. The patient received advice regarding daily exercise.
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a major public health issue resulting in chronic morbidity and mortality in global populations. The World Health Organisation estimates that over 65 million people globally have moderate to severe COPD (1). COPD was the third leading cause of death in 2012 with 3.1 million (5.6%) of global deaths directly attributed to COPD (2). This figure is projected to rise to 8.6% by 2030 (3).
COPD affects over 23 million people in the EU and results in an estimated 1.1 million hospital admissions in the region per annum (3). Ireland has one of the highest rates of hospital admissions for exacerbations of COPD in the OECD at 364 per 100,000 compared to 198 per 100,000 for the OECD (4). In 2011, the age standardised death rate for COPD was 27.87 per 100,000 for Ireland compared with 18 per 100,000 for the WHO European region (3).
Patients with COPD experience a wide variations in their level of disability (5).
Several studies have shown that pulmonary rehabilitation can greatly benefit patients with COPD by reducing symptoms, improving activity and functional levels leading to a reduction in the overall burden on the health care system (6, 7).
Definition
COPD is a preventable and progressive disease characterized by persistent airflow limitation and associated with a chronic inflammatory response in the airways and lung to noxious particles or gases such as those found in tobacco smoke (8). The frequency of exacerbations and severity of pre-existing comorbidities contribute to disability. A diagnosis of COPD is made in the correct clinical context using spirometry (8).
Diagnostic Criteria
Spirometry with a postbrochodilator FEV1–FVC ratio less than 0.7 is diagnostic of COPD in combination with symptoms and in the absence of an alternative explanation for the symptoms of airflow obstruction (9). Despite a poor correlation with symptom burden disease severity is often described using spirometric indices.
Global Initiative for Chronic Obstructive Lung Disease (GOLD)
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) produce regularly updated guidelines that define the main goals of assessment of COPD to determine the severity of the disease, the severity of airflow limitation, the impact on the patient’s health status, the risk of future events including exacerbations, hospital admissions, or death, in order to guide treatment (10).
GOLD recommends that comorbidities such as cardiovascular disease, metabolic syndrome, osteoporosis, depression, and lung cancer should be actively managed and optimised in order to reduce the impact on the patient's overall health (10).
Management of Stable COPD
All individuals who smoke should be encouraged to quit (8). The FEV1 value is a poor guide to the impact of the disease on patients (8). Consequently, each patient must be assessed in terms of their symptoms and future risk of exacerbation. This should also be incorporated into an individualised management strategy for stable COPD.
Influenza vaccines can reduce the risk of serious illness including hospital admissions due to lower respiratory tract infection and death in COPD patients by approximately 50% (11).
Pharmacologic therapy is used to reduce symptoms as well as the frequency and severity of exacerbations. It can also improve health status and exercise tolerance. Long acting beta2 -agonists and anticholinergics are preferred over short-acting formulations. Based on efficacy and side effects, inhaled bronchodilators are preferred over oral bronchodilators. Long-term treatment with inhaled corticosteroids added to long-acting bronchodilators are recommended for patients at high risk of exacerbations. Long-term monotherapy with oral or inhaled corticosteroids is not recommended. The phosphodiesterase-4 inhibitor roflumilast may be useful to reduce exacerbations for patients with FEV1 < 50% predicted, chronic bronchitis, and frequent exacerbations (10).
Assessment COPD
The main aims of assessing a patient with COPD are to determine: 1. The impact of the disease of the patient's overall health status in terms of symptoms and restriction on daily functions 2. the extent of airflow limitation 3. the risk of hospital admissions, exacerbations or death and 4. the presence of comorbidities that may be exacerbating the symptoms (8). This information is used to guide treatment of the disease.
There are several tools that are used to assess the severity symptoms in a patient with COPD including the modified Medical Research Council Scale (mMRC), COPD Assessment Test (CAT), St George's Respiratory Questionnaire (SGRQ) and the BODE Index. GOLD recommends using the mMRC or the CAT to assess the severity of symptoms with higher scores indicating greater impact on the patient’s daily life (8).
Combined COPD Assessment
A combined COPD assessment involves categorising the severity of airflow obstruction in terms of the FEV1. The grading ranges from GOLD stage 1 to 4. Stage 1 indicates mild airflow limitation with FEV1 >80% predicted while stage 4 indicates severe airflow limitation with FEV1 <30% predicted. This staging is used in combination with a symptom assessment, either the mMRC or CAT scores, with exacerbation frequency to give an indication as to the severity of symptoms. If the patient has 2 or more exacerbations in the preceding year this indicates the patient is at high risk for further exacerbations. A combination of FEV1 staging, mMRC or CAT scores and the number of exacerbations allows the patient to be staged as GOLD A, B, C or D.
Modified Medical Research Council Scale (mMRC)
There are several tools available that can be used to assess the level of disability due to COPD including the mMRC, CAT, Chronic Respiratory Disease Questionnaire (CRQ), Clinical COPD Questionnaire (CCQ) and the St George's Respiratory Questionnaire (SGRQ) (5). While some of these are quite complex to administer, the mMRC provides a simple method to grade the effect of dyspnoea on a patient's daily activities and mobility (5). The scale is subjective measuring a patient’s perceived respiratory disability. It is a 5 point scale graded from 0 to 4 with those who have dyspnoea only during rigorous exercise scoring 0, while those who are too breathless to leave home scoring 4. The mMRC is used to calculate the BODE Index which is a tool used to predict the life expectancy for a patient with COPD.
COPD Assessment Tool (CAT)
The CAT was developed to provide healthcare professionals with a simple tool for quantifying the severity of symptoms in a patient with COPD (12). CAT consists of eight items, each presented on a 6-point differential scale, providing a score out of 40 which indicates the impact of the disease (12). It is completed by the patient and the result is immediately available by adding together the scores on individual items. Scores of 0–10, 11– 20, 21–30 and 31–40 represent mild, moderate, severe or very severe clinical impact (12). The CAT is freely available online at www.catestonline.org.
BODE Index
The BODE index is a tool used to grade the severity of COPD based on BMI,
airflow Obstruction, Dyspnea, and Exercise. The severity of airflow obstruction is indicated by the FEV1, dyspnea is measured using the mMRC and exercise tolerance is indicated by the 6 minute walk test. The BODE index is an excellent predictor of the risk of death in patients with COPD (13). The BODE index provides a comprehensive assessment as it includes one domain that quantifies the degree of pulmonary impairment (FEV1), one that captures the patient’s perception of symptoms (the mMRC dyspnoea scale), and two independent domains (the distance walked in six minutes and the body-mass index) that express the systemic consequences of COPD (13).
St George's Respiratory Questionnaire (SGRQ)
The SGRQ is designed to measure health impairment in patients with asthma and COPD (14). The questionnaire assesses three main areas including symptoms, activity and impacts (14). The symptoms component is concerned with the effect of respiratory symptoms including their frequency and severity while the activity part looks at which activities cause or are limited by dyspnoea. The impact section looks at the psychosocial disturbances that may result from COPD. A Total score is calculated which summarises the impact of the disease on overall health status. Scores are expressed as a percentage of overall impairment, where 100 represents worst possible health status and 0 indicates the best possible health status (14). This questionnaire can be time consuming to administer and while sensitive to clinically significant changes in health status is often limited to research settings.
HADS score
Hospital anxiety and depression scale (HADS) is a tool commonly used to determine the levels of anxiety or depression in people with physical health problems (15). There are fourteen items on the scale, seven of which refer to anxiety and seven to depression. Each item is scored from 0 to 3 and a maximum score of 21 for both anxiety and depression. A score greater than 8 indicates some psychological distress with higher scores indicating greater severity (15). HADS can be applied to a patient with any disease. A study by Dowson et al showed that clinically relevant anxiety, indicated by higher HADS scores, was more common in patients with severe COPD (16).
Conclusion
COPD is a common chronic and progressive condition. It has a significant impact on health status. Health resources and medical interventions often focus on the acutely unstable patient or those in exacerbation. The patient however spends longer in a chronic stable state than acute crisis. Treatment decisions taken in the management of stable patients have implications both for exacerbation frequency and overall quality of life. Interventions include pharmacotherapy, psychosocial support and physical therapy. A range of well validated tools now exist to assist the physician in defining disease severity and tailoring the therapeutic response.
References
1. WHO. Burden of COPD World Health Organisation Website: World Health Organisation; 2015 [cited 2015 10/10/15]. Available from: http://www.who.int/respiratory/copd/burden/en/.
2. WHO. Fact Sheet 310: The Top 10 Causes of Death WHO website: World Heath Organisation; 2014 [cited 2015]. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/.
3. Book ELW. The Burden of Lung Disease: ELWB; 2015 [cited 2015 13/10/15]. Figure 7]. Available from: http://www.erswhitebook.org/chapters/the-burden-of-lung-disease/.
4. Gay JG, Paris V, Devaux M, Looper Md. Mortality amenable to health care in 31 OECD countries: Estimates and Methodological Issues. Health Working Papers [Internet]. 2011 [cited 2015 13/10/15]:[39 p.]. Available from: http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=DELSA/HEA/WD/HWP(20 11)1&docLanguage=En.
5. Bestall J, Paul E, Garrod R, Garnham R, Jones P, Wedzicha J. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581-6.
6. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;4(4).
7. Seymour JM, Moore L, Jolley CJ, Ward K, Creasey J, Steier JS, et al. Outpatient pulmonary rehabilitation following acute exacerbations of COPD. Thorax. 2010;65(5):423-8.
8. GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease GOLD website: Global Initiative for Chronic Obstructive Lung Disease; 2015 [cited 2015 11/10/15]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2015_Sept2.pdf.
9. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, Van der Molen T, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Annals of internal medicine. 2011;155(3):179- 91.
10. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2012.
11. Nichol K, Margolis K, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. New England journal of medicine. 1994;331(12):778-84.
12. Jones P, Harding G, Berry P, Wiklund I, Chen W, Leidy NK. Development and first validation of the COPD Assessment Test. European Respiratory Journal. 2009;34(3):648-54.
13. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body- mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. New England Journal of Medicine. 2004;350(10):1005-12.
14. Jones PW, Quirk F, Baveystock C. The St George's respiratory questionnaire. Respiratory medicine. 1991;85:25-31.
15. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta psychiatr scand. 1983;67(6):361-70.
16. Dowson C, Laing R, Barraclough R, Town I, Mulder R, Norris K, et al. The use of the Hospital Anxiety and Depression Scale (HADS) in patients with chronic obstructive pulmonary disease: a pilot study. The New Zealand Medical Journal. 2001;114(1141):447-9.